GlobeNewswire
Source: Penwest Pharmaceuticals Co.
In the Phase Ib trial, the drug was well tolerated by subjects, and no serious adverse events were reported. There was a dose-dependent increase in exposure approaching steady state within 2-4 days following repeat-dosing, and a maximum tolerated dose was established.
Plans to Advance A0001 Into Phase IIa Trials in Patients in Second Half of 2009
http://www.penw.com/
http://health.groups.yahoo.com/group/FA_babelFAmily/message/3058
Thursday, July 16, 2009
UA Professors receive over $1.45 million in grants
Money to fund researching neurological diseases
The Crimson White, Published: Thursday, July 16, 2009
.../...
While they are researching different topics, both professors are focusing on certain proteins found in the body and their roles in neurological diseases. Busenlehner’s research focuses on a neurodegenerative disease called Friedreich’s ataxia, which is caused by decreased levels of the protein frataxin.
“What we are wanting to know is what is the exact function of this protein, frataxin, in the human body,” Busenlehner said.
.../...
The Crimson White, Published: Thursday, July 16, 2009
.../...
While they are researching different topics, both professors are focusing on certain proteins found in the body and their roles in neurological diseases. Busenlehner’s research focuses on a neurodegenerative disease called Friedreich’s ataxia, which is caused by decreased levels of the protein frataxin.
“What we are wanting to know is what is the exact function of this protein, frataxin, in the human body,” Busenlehner said.
.../...
Subscribe to:
Posts (Atom)
